Skip to content
The Policy VaultThe Policy Vault

Imbruvica (ibrutinib tablets, capsules, and oral suspension) — Cigna

Hairy Cell Leukemia

Initial criteria

  • Patient is age ≥ 18 years
  • Patient has tried at least two systemic regimens

Approval duration

1 year